Biotech’s Q2 numbers paint a picture of the good, the bad and the uglynews2025-07-10T11:00:17+00:00July 10th, 2025|Endpoints News|
AbbVie bags Capstan’s in vivo CAR-T work with $2.1B buyout dealnews2025-06-30T12:36:58+00:00June 30th, 2025|Endpoints News|
Federally-funded cancer research comes to a perilous crossroadsnews2025-06-09T17:21:34+00:00June 9th, 2025|Endpoints News|
Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontentnews2025-05-20T11:00:54+00:00May 20th, 2025|Endpoints News|
As the XBI suffers, Q1 shows a few comforting signs of underlying stabilitynews2025-04-22T11:00:22+00:00April 22nd, 2025|Endpoints News|
Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15news2025-04-01T11:00:51+00:00April 1st, 2025|Endpoints News|
Where the money is: The top 100 venture investors in biotechnews2025-02-25T12:00:57+00:00February 25th, 2025|Endpoints News|
A mixed year for deals and dollars left biotech execs hungry for a better 2025news2025-01-16T12:00:39+00:00January 16th, 2025|Endpoints News|
The Endpoints 100 Survey: Biotech industry braces for Trump 2.0news2024-12-11T12:00:55+00:00December 11th, 2024|Endpoints News|
